Iscartrelvir

Iscartrelvir

Clinical data
Other names	WPV01; WU-04
Identifiers
IUPAC name N-[(1S,2R)-2-[4-bromo-2-(methylcarbamoyl)-6-nitroanilino]cyclohexyl]isoquinoline-4-carboxamide
CAS Number	2921711-74-0
PubChem CID	156774920
ChemSpider	129307041
UNII	W2LTV65R5E
PDB ligand	J7R ( PDBe , RCSB PDB )
Chemical and physical data
Formula	C24H24BrN5O4
Molar mass	526.391 g·mol−1
3D model (JSmol)	Interactive image
SMILES CNC(=O)C1=C(C(=CC(=C1)Br)[N+](=O)[O-])N[C@@H]2CCCC[C@@H]2NC(=O)C3=CN=CC4=CC=CC=C43
InChI InChI=InChI=1S/C24H24BrN5O4/c1-26-23(31)17-10-15(25)11-21(30(33)34)22(17)28-19-8-4-5-9-20(19)29-24(32)18-13-27-12-14-6-2-3-7-16(14)18/h2-3,6-7,10-13,19-20,28H,4-5,8-9H2,1H3,(H,26,31)(H,29,32)/t19-,20+/m1/s1 Key:BPLNOSFMIIASSJ-UXHICEINSA-N

Iscartrelvir is an investigational new drug developed by the Westlake University for the treatment of COVID-19. It targets the SARS-CoV-2 3CL protease, which is crucial for the replication of the virus responsible for COVID-19. ^{[1] [2]}

See also

• 3CLpro-1
• Rupintrivir

References

1. Yang L, Wang Z (September 2023). "Bench-to-bedside: Innovation of small molecule anti-SARS-CoV-2 drugs in China". European Journal of Medicinal Chemistry. 257: 115503. doi:10.1016/j.ejmech.2023.115503. PMC   10193775 . PMID   37229831.
2. Hou N, Shuai L, Zhang L, Xie X, Tang K, Zhu Y, et al. (February 2023). "Development of Highly Potent Noncovalent Inhibitors of SARS-CoV-2 3CLpro". ACS Central Science. 9 (2): 217–227. doi:10.1021/acscentsci.2c01359. PMC   9885526 . PMID   36844503.